Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection

被引：17
|
作者：
Wessels, Uwe [1 ]
Zadak, Markus [1 ]
Reiser, Astrid [1 ]
Brockhaus, Janis [2 ]
Ritter, Mirko [2 ]
Abdolzade-Bavil, Afsaneh [1 ]
Heinrich, Julia [1 ]
Stubenrauch, Kay [1 ]
机构：
[1] Roche Innovat Ctr Munich, Pharma Res & Early Dev, Pharmaceut Sci, Nonnenwald 2, D-82377 Penzberg, Germany
[2] Roche Diagnost GmbH, Roche Innovat Ctr Munich, Nonnenwald 2, D-82377 Penzberg, Germany
来源：
BIOANALYSIS | 2018年 / 10卷 / 11期
关键词：
antidrug antibody; aqueous humor; drug tolerance; ELISA; immune complex assay; immunogenicity; ophthalmology; safety assessment; vitreous humor; DRUG TOLERANCE; BIOTECHNOLOGY PRODUCTS; MACULAR DEGENERATION; TARGET INTERFERENCE; VITREOUS-HUMOR; SERUM SAMPLES; ASSAYS; RECOMMENDATIONS; PHARMACOKINETICS; RANIBIZUMAB;
D O I：
10.4155/bio-2018-0047
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Aim: High drug concentrations in ocular fluids after intravitreal administration preclude the use of drugsensitive immunoassays. A drug-tolerant immunoassay is therefore desirable for immunogenicity testing in ophthalmology. Experimental: Immune complex (IC) antidrug antibody (ADA) assays were established for two species. The assays were compared with the bridging assay in ocular and plasma samples from two preclinical studies. Results: The IC assays showed high drug tolerance, which enabled a reliable ADA detection in ocular fluids after intravitreal administration. The IC assays were superior to the bridging assay in the analysis of ocular fluids with high drug concentrations. Conclusion: The IC assay allows a reliable ADA detection in matrices with high drug concentrations, such as ocular fluids.
引用
收藏
页码：803 / 814
页数：12
相关论文
共 50 条
  • [1] Ocular Pain After Intravitreal Injection
    Rosa Sanabria, Maria
    Montero, Javier A.
    Victoria Losada, Maria
    Fernandez-Munoz, Marta
    Galindo, Alicia
    Fernandez, Itziar
    Coco, Rosa M.
    Sampedro, Ana
    CURRENT EYE RESEARCH, 2013, 38 (02) : 278 - 282
  • [2] Ocular hypertension after intravitreal injection, foreword
    Denis, Philippe
    Pisella, Piere-Jean
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2017, 40 (03): : 237 - 238
  • [3] OCULAR TOXICITY AFTER INTRAVITREAL INJECTION OF TERCONAZOLE
    SCHULMAN, JA
    PEYMAN, GA
    DIETLEIN, J
    FISCELLA, R
    COLANTINO, B
    ANNALS OF OPHTHALMOLOGY, 1989, 21 (09): : 345 - 347
  • [4] Ocular hypertension after intravitreal injection: Screening and management
    Poli, M.
    Denis, P.
    Dot, C.
    Nordmann, J. -P.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2017, 40 (03): : E77 - E82
  • [5] Ocular distribution of bioresorbable nanoparticles after intravitreal and subretinal injection
    Gautier, SE
    Behar-Cohen, F
    Salvodelli, M
    Jerome, R
    Chauvaud, D
    Renard, G
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S83 - S83
  • [6] OCULAR FINDINGS 6 YEARS AFTER INTRAVITREAL SILICONE INJECTION
    SUGAR, HS
    OKAMURA, ID
    ARCHIVES OF OPHTHALMOLOGY, 1976, 94 (04) : 612 - 615
  • [7] Immunogenicity of therapeutic antibodies
    Stas, Philippe
    Lasters, Ignace
    M S-MEDECINE SCIENCES, 2009, 25 (12): : 1070 - 1077
  • [8] Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing
    Rispens, Theo
    de Vrieze, Henk
    de Groot, Els
    Wouters, Diana
    Stapel, Steven
    Wolbink, Gerrit J.
    Aarden, Lucien A.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2012, 375 (1-2) : 93 - 99
  • [9] Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
    Kocabora, M. Selim
    Yilmazli, Cemil
    Taskapili, Muhittin
    Gulkilik, Gokhan
    Durmaz, Sahan
    CLINICAL OPHTHALMOLOGY, 2008, 2 (01): : 167 - 171
  • [10] Ocular changes after intravitreal injection of methanol, formaldehyde, or formate in rabbits
    Hayasaka, Y
    Hayasaka, S
    Nagaki, Y
    PHARMACOLOGY & TOXICOLOGY, 2001, 89 (02): : 74 - 78
12345